Abstract: A modified coxsackievirus showing improved safety and/or aggressiveness to be used for oncolytic virotherapy is provided. A modified coxsackievirus showing tissue-specific suppression of proliferation and comprising a mutated genome consisting of the genome of coxsackievirus B3 wild-type (CVB3-WT) inserted with at least one polynucleotide consisting of a target sequence of tissue-specific microRNA (miRNA) is provided. The mutated genome is preferably further inserted with the region encoding GM-CSF in an expressible form.
Type:
Grant
Filed:
April 17, 2014
Date of Patent:
September 18, 2018
Assignees:
SHIN NIHON SEIYAKU CO., LTD, KYUSHU UNIVERSITY NATIONAL UNIVERSITY CORPORATION